title: Bioequivalence of ciprofloxacin tablet formulations assessed in Indonesian volunteers.
abstract: OBJECTIVE
  Determination of the bioequivalence of two ciprofloxacin tablet formulations (test formulation manufactured by Novell Pharmaceutical Laboratories, Indonesia, reference formulation from Quimica Farmaceutica Bayer, Spain).
  
  
  METHODS
  24 healthy volunteers received each of the two ciprofloxacin formulations at a dose of 500 mg in a 2-way crossover design. Blood samples were obtained prior to dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and24h after drug administration. Plasma concentrations of ciprofloxacin were monitored using high-performance liquid chromatography over a period of 24 h after administration. The pharmacokinetics parameter AUC0-24h, AUC0-infinity and Cmax were tested for bioequivalence after log-transformation of data and ratios of tmax were evaluated non-parametrically.
  
  
  RESULTS
  The point estimates and 90% confidence intervals for AUC0-24h, AUC0-infinity and Cmax were 97.55% (92.71 - 102.6%), 97.63% (92.90 - 102.59%) and 95.84% (89.95 - 102.10%), respectively, satisfying the bioequivalence criteria of the European Committee for Proprietary Medicinal Products and the US Food and Drug Administration guidelines.
  
  
  CONCLUSIONS
  These results indicate that two medications of ciprofloxacin are bioequivalent and, thus, may be prescribed interchangeably.
authors.affiliation: Department of Pharmacy, Faculty of Mathematics and Sciences, University of Indonesia. yahdiana03@yahoo.com
authors.forename: Y
authors.initials: Y
authors.lastname: Harahap
authors.forename: B
authors.initials: B
authors.lastname: Prasaja
authors.forename: E
authors.initials: E
authors.lastname: Indriati
authors.forename: W
authors.initials: W
authors.lastname: Lusthom
authors.lastname: Lipin
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019540:Area Under Curve; D002626:Chemistry, Pharmaceutical; D002851:Chromatography, High Pressure Liquid; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D018592:Cross-Over Studies; D005260:Female; D006207:Half-Life; D006801:Humans; D007214:Indonesia; D008297:Male; D013607:Tablets; D013810:Therapeutic Equivalency
chemical_list: D000900:Anti-Bacterial Agents; D013607:Tablets; D002939:Ciprofloxacin